Search | Clinical Trials Finder

Conditions: Multiple Sclerosis
Interventions: Teriflunomide, Placebo; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 4
States / cities: Cullman, Alabama • Tampa, Florida • Boston, Massachusetts + 1 more

Conditions: Multiple Sclerosis
Interventions: Ocrelizumab, Rituximab; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 65 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Relapsing Multiple Sclerosis
Interventions: Ofatumumab, [F-18]PBR06; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 60 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis
Interventions: Ublituximab; Drug
Lead sponsor: Neurology Center of New England P.C.; Other
Eligibility: 55 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Foxborough, Massachusetts

Conditions: Multiple Sclerosis
Interventions: Diroximel Fumarate, Alemtuzumab, Fingolimod, Glatiramer acetate, Interferon beta, Natalizumab, Ocrelizumab, Ofatumumab, Ozanimod, Peginterferon beta-1a, Ponesimod, Siponimod; Drug · Biological
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 1,178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 1
States / cities: Eden Prairie, Minnesota

Conditions: Multiple Sclerosis, Relapse
Interventions: Not listed
Lead sponsor: John F. Foley, MD; Other
Eligibility: 18 Years to 75 Years
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Relapsing Multiple Sclerosis
Interventions: natalizumab; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 11
States / cities: Fullerton, California • Aurora, Colorado • Des Moines, Iowa + 8 more

Conditions: Multiple Sclerosis
Interventions: Interferon-beta-1a FBS-free/HSA-free; Biological
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Rockland, Massachusetts

Conditions: Multiple Sclerosis
Interventions: ELND002, Placebo; Drug
Lead sponsor: Elan Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 17
States / cities: Berkeley, California • Fresno, California • Newport Beach, California + 14 more

Conditions: Relapsing Multiple Sclerosis (RMS)
Interventions: Ublituximab, Teriflunomide, Oral Placebo, IV Placebo; Biological · Drug
Lead sponsor: TG Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 545 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 13
States / cities: Phoenix, Arizona • Aurora, Colorado • Tampa, Florida + 10 more

Conditions: Multiple Sclerosis, Healthy
Interventions: Not listed
Lead sponsor: University at Buffalo; Other
Eligibility: 18 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: Ublituximab; Biological
Lead sponsor: TG Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 8
States / cities: Pasadena, California • Aurora, Colorado • Lexington, Kentucky + 5 more

Conditions: Multiple Sclerosis, Relapsing Multiple Sclerosis, Advancing Multiple Sclerosis
Interventions: Siponimod; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 54
States / cities: Birmingham, Alabama • Cullman, Alabama • Homewood, Alabama + 49 more

Conditions: Relapsing Multiple Sclerosis
Interventions: Tolebrutinib, Teriflunomide HMR1726, Placebo to match Tolebrutinib, Placebo to match Teriflunomide; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 899 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 43
States / cities: Cullman, Alabama • Phoenix, Arizona • Arcadia, California + 38 more

Conditions: Multiple Sclerosis
Interventions: Rebif®; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Multiple Sclerosis (MS)
Interventions: elezanumab, placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 42
States / cities: Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 35 more

Conditions: Relapsing Forms of MS
Interventions: Diroximel Fumarate; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 18
States / cities: West Hollywood, California • Washington D.C., District of Columbia • Louisville, Kentucky + 15 more

Conditions: Multiple Sclerosis
Interventions: BIIB033, Placebo, Avonex; Drug · Other
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 58 Years
Enrollment: 419 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 11
States / cities: Cullman, Alabama • Phoenix, Arizona • Raleigh, California + 8 more

Conditions: Relapsing-Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
Interventions: Autologous mesenchymal stem cell transplantation; Biological
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Multiple Sclerosis
Interventions: Diroximel Fumarate, Avonex, Tysabri, Dimethyl Fumarate; Drug · Biological
Lead sponsor: Biogen; Industry
Eligibility: Female only
Enrollment: 908 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 2
States / cities: Aurora, Colorado • Durham, North Carolina

Conditions: Relapsing Forms of Multiple Sclerosis
Interventions: Fingolimod, Standard MS DMTs; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,053 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 142
States / cities: Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 125 more

Conditions: Relapsing Multiple Sclerosis, Clinically Isolated Syndrome, Relapsing-remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Interventions: Not listed
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Relapsing Multiple Sclerosis, Clinically Isolated Syndrome, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Interventions: Not listed
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Multiple Sclerosis
Interventions: Cladribine, Placebo, Interferon-beta (IFN-beta); Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 21
States / cities: Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 18 more

Search by objective public record fields.

Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis

Safety of Switching From Rituximab to Ocrelizumab in MS Patients

9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple Sclerosis

A Single-Center Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS)

A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies

Pharmacokinetic, Immunological and Biochemical Sample Collection and Analysis of a Tysabri Patient Cohort

Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies

Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis

A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis

Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS)

Effects of Gilenya (Fingolimod) on Thalamus Pathology and Cognitive Impairment in Patients With Relapsing Forms of Multiple Sclerosis

An Extension of the TG1101-RMS201 Trial

Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients

Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)

RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate

A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis

Study of Diroximel Fumarate in the Real-World Setting

Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex

Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS

Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)

A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis

Study to Assess Changes in Immunoglobulins in Patients With Relapsing Multiple Sclerosis Treated With Anti-CD20 Therapies

A Study to Assess the Effectiveness and Safety of Mayzent in Chinese Patients With Relapsing Forms of Multiple Sclerosis

A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD)